SCHEMBL20122794

SCHEMBL20122794

CCn1c2cnccc2c2cc(Cl)cc(-c3ccccc3Cl)c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 7/20 0.41
CHEK1 O14757 1/20 0.39
WEE1 P30291 1/20 0.39
KDM5A P29375 1/20 0.38
PDE2A O00408 1/20 0.37
PDE4D Q08499 1/20 0.37
PDE11A Q9HCR9 1/20 0.37
PDE10A Q9Y233 1/20 0.37
METAP2 P50579 2/20 0.36
LIMK1 P53667 2/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
HDAC2 Q92769 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
EGFR P00533 1/20 0.35
FGFR1 P11362 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664295 1.00 ROCK2 (0.41) ROCK2CHEK1WEE1KDM5APDE2A
SCHEMBL30664211 0.86 KDM4E (0.44) ROCK2KDM5AMETAP2CYP1A2MAPT
SCHEMBL20122825 0.86 KDM4E (0.44) ROCK2KDM5AMETAP2CYP1A2MAPT
SCHEMBL20122892 0.84 METAP2 (0.44) ROCK2KDM5AMETAP2CYP1A2KCNH2
SCHEMBL30664293 0.84 METAP2 (0.44) ROCK2KDM5AMETAP2CYP1A2KCNH2
SCHEMBL30664279 0.83 ROCK2 (0.43) ROCK2KDM5AMETAP2CYP1A2CYP3A4
SCHEMBL20122870 0.83 ROCK2 (0.43) ROCK2KDM5AMETAP2CYP1A2CYP3A4
SCHEMBL20123010 0.83 ROCK2 (0.40) ROCK2KDM5AMETAP2CYP1A2KCNH2
SCHEMBL30664221 0.83 ROCK2 (0.40) ROCK2KDM5AMETAP2CYP1A2KCNH2
SCHEMBL30664233 0.82 ROCK2 (0.39) ROCK2KDM5AMETAP2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 ROCK2 1093/4885CHEK1 3696/4885WEE1 4432/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 ROCK2 1093/4885CHEK1 3696/4885WEE1 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.